Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastiano Buti

Showing results (11-20 of 335) with videos related to

Pageof 34
Sort By:
The Lancet. Oncology|October 22, 2013
Axitinib dose titration: what's the limiting factor?Sebastiano Buti, Camillo Porta
The New England Journal of Medicine|December 16, 2020
Avelumab Maintenance for Urothelial CarcinomaSebastiano Buti, Melissa Bersanelli
The Lancet Regional Health. Europe|March 19, 2025
The Italian hospital medical profession is broken tooSebastiano Buti, Giuseppe Fornarini
The New England Journal of Medicine|February 18, 2016
Drug-Induced Megaloblastic AnemiaSebastiano Buti, Angelica Sikokis
Acta Bio-Medica : Atenei Parmensis|May 11, 2016
Upfront Chemohormonal Therapy for Prostate Cancer: Neutropenia and G-CSF UseSebastiano Buti, Melissa Bersanelli
The Lancet. Oncology|March 15, 2016
Non-clear-cell renal carcinoma therapy: handle with careSebastiano Buti, Melissa Bersanelli
Recent Patents on Anti-Cancer Drug Discovery|July 3, 2010
Renal cell cancer: state of the art in adjuvant therapySebastiano Buti, Rodrigo K Rovere
Urologic Oncology|April 17, 2022
Comparing the prognostic models to predict oncologic outcomes in patients with renal cell carcinoma: is AUC close enough to clinical practice?Sebastiano Buti, Giulia Claire Giudice
Annals of Surgical Oncology|June 4, 2024
Comparing a Part with the Whole: Beware of the Disparity of the Renal Cell Carcinoma Prognostic ModelsSebastiano Buti, Giulia Claire Giudice
Immunotherapy|October 26, 2017
The link between calcitriol and anticancer immunotherapy: vitamin D as the possible balance between inflammation and autoimmunity in the immune-checkpoint blockadeMelissa Bersanelli, Alessandro Leonetti, Sebastiano Buti
Pageof 34

Showing results (11-20 of 335) with videos related to

Sort By:
Pageof 34
The Lancet. Oncology|October 22, 2013
Axitinib dose titration: what's the limiting factor?Sebastiano Buti, Camillo Porta
The New England Journal of Medicine|December 16, 2020
Avelumab Maintenance for Urothelial CarcinomaSebastiano Buti, Melissa Bersanelli
The Lancet Regional Health. Europe|March 19, 2025
The Italian hospital medical profession is broken tooSebastiano Buti, Giuseppe Fornarini
The New England Journal of Medicine|February 18, 2016
Drug-Induced Megaloblastic AnemiaSebastiano Buti, Angelica Sikokis
Acta Bio-Medica : Atenei Parmensis|May 11, 2016
Upfront Chemohormonal Therapy for Prostate Cancer: Neutropenia and G-CSF UseSebastiano Buti, Melissa Bersanelli
The Lancet. Oncology|March 15, 2016
Non-clear-cell renal carcinoma therapy: handle with careSebastiano Buti, Melissa Bersanelli
Recent Patents on Anti-Cancer Drug Discovery|July 3, 2010
Renal cell cancer: state of the art in adjuvant therapySebastiano Buti, Rodrigo K Rovere
Urologic Oncology|April 17, 2022
Comparing the prognostic models to predict oncologic outcomes in patients with renal cell carcinoma: is AUC close enough to clinical practice?Sebastiano Buti, Giulia Claire Giudice
Annals of Surgical Oncology|June 4, 2024
Comparing a Part with the Whole: Beware of the Disparity of the Renal Cell Carcinoma Prognostic ModelsSebastiano Buti, Giulia Claire Giudice
Immunotherapy|October 26, 2017
The link between calcitriol and anticancer immunotherapy: vitamin D as the possible balance between inflammation and autoimmunity in the immune-checkpoint blockadeMelissa Bersanelli, Alessandro Leonetti, Sebastiano Buti
Pageof 34